Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study.

My-Linh Tran-MinhJean-Marc GornetMarianne MailletPascal HouzeMarion SimonPaul McLellanDeborah HassidJustine Vivier-ChicoteauClotilde BaudryNassim HammoudiMatthieu Allez

Published in: Journal of Crohn's & colitis (2021)

Hydrocortisone discontinuation is safe in IBD patients with sustained clinical remission on maintenance therapy with IFX. Our data suggest that routine premedication with hydrocortisone is unnecessary in patients in prolonged remission under IFX maintenance therapy.

Keyphrases

ulcerative colitis
end stage renal disease
patients with inflammatory bowel disease
ejection fraction
newly diagnosed
chronic kidney disease
rheumatoid arthritis
stem cells
machine learning
prognostic factors
disease activity
mesenchymal stem cells
clinical practice
peritoneal dialysis
big data
bone marrow